Psychopharmacological treatment for military posttraumatic stress disorder: An integrative review
Jennifer Tawa was not employed by or affiliated with any United States Veterans Administration or the U.S. government during the composition period of this manuscript. The views reflected within this manuscript are not those of the USVA or military.
Jennifer Tawa, APRN, Center for Life Management, 10 Tsienneto Road, Derry, NH 03038. Tel: 603-434-1577; Fax: 603-930-4746; E-mail: email@example.com
Posttraumatic stress disorder (PTSD) is a serious mental health disorder. The current first-line psychopharmacologic treatment for PTSD is selective serotonin reuptake inhibitors (SSRIs). Recently, the efficacy of SSRIs has been challenged in favor of propranolol use. This article reviews the origins of PTSD, its impact within the veteran population, psychopharmacological treatment of PTSD, and current literature on the use of propranolol for PTSD treatment.
The search strategies used included ProQuest, Medline, CINAHL, and Psychiatry Online and were searched using the key terms: PTSD, psychopharmacological treatment, SSRIs, propranolol, military, and veterans in multiple combinations.
Studies to date indicate that (a) SSRIs are only moderately effective as a first-line treatment for PTSD and less so for military personnel, (b) propranolol has the ability to attenuate traumatic memory in primary and tertiary use, and (c) ethical and moral consideration as well as further research and testing is needed for substantiating propranolol as a first-line PTSD psychopharmacological treatment.
Implications for practice
Current research has shown propranolol to be an effective treatment option for PTSD.